Trine J. Nottrup

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Journal: Gynecologic oncology

Published: March 24, 2026

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 04, 2026

Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy-the DANGER-emesis study.

Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy-the DANGER-emesis study.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: December 23, 2024

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 21, 2023

PD-L1 expression in vulvar cancer: a systematic review and meta-analysis.

PD-L1 expression in vulvar cancer: a systematic review and meta-analysis.

Journal: Histopathology

Published: October 11, 2023

Clinical experiences with online adaptive radiotherapy of vulvar carcinoma.

Clinical experiences with online adaptive radiotherapy of vulvar carcinoma.

Journal: Acta oncologica (Stockholm, Sweden)

Published: September 15, 2023

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.

Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.

Journal: Oncogene

Published: May 31, 2023

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation.

Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation.

Journal: Cancers

Published: May 17, 2023

Disseminated Primary Uterine Hepatoid Adenocarcinoma with α-Fetoprotein Production Demonstrated on 18F-FDG PET/CT.

Disseminated Primary Uterine Hepatoid Adenocarcinoma with α-Fetoprotein Production Demonstrated on 18F-FDG PET/CT.

Journal: Diagnostics (Basel, Switzerland)

Published: May 25, 2022

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.

Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 19, 2022

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

Journal: Gynecologic oncology

Published: October 14, 2021

Toward PET/MRI as one-stop shop for radiotherapy planning in cervical cancer patients.

Toward PET/MRI as one-stop shop for radiotherapy planning in cervical cancer patients.

Journal: Acta oncologica (Stockholm, Sweden)

Published: June 10, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026